

Ileana Mardare

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4658050/ileana-mardare-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

348
citations

10
h-index

18
g-index

19
ext. papers

524
ext. citations

3.6
avg, IF

3.01
L-index

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 17 | Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. <i>Frontiers in Public Health</i> , 2018 , 6, 328 | 6 | 68 |
| 16 | The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. <i>Pharmacoeconomics</i> , 2017 , 35, 1271-1285 | 4.4 | 64 |
| 15 | COVID-19 pandemic and alcohol consumption: Impacts and interconnections. <i>Toxicology Reports</i> , 2021 , 8, 529-535 | 4.8 | 45 |
| 14 | Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020 , 20, 1-26 | 2.2 | 33 |
| 13 | Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. <i>Frontiers in Pharmacology</i> , 2017 , 8, 497 | 5.6 | 26 |
| 12 | The Expiry of Humira Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. <i>Frontiers in Pharmacology</i> , 2020 , 11, 591134 | 5.6 | 21 |
| 11 | Pricing of oral generic cancer medicines in 25 European countries; findings and implications. <i>GaBI Journal</i> , 2019 , 8, 49-70 | 3.1 | 20 |
| 10 | Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019 , 19, 251-261 | 2.2 | 19 |
| 9 | Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. <i>Applied Health Economics and Health Policy</i> , 2020 , 18, 5-16 | 3.4 | 18 |
| 8 | Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 527-540 | 2.2 | 11 |
| 7 | The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. <i>Frontiers in Public Health</i> , 2021 , 9, 671961 | 6 | 9 |
| 6 | Evidence-based public policy making for medicines across countries: findings and implications for the future. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 1019-1052 | 2.1 | 7 |
| 5 | Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. <i>BioMed Research International</i> , 2021 , 2021, 9996193 | 3 | 2 |
| 4 | Measuring Stress [Methods and Tools. <i>Acta Medica Transilvanica</i> , 2020 , 25, 5-7 | 0 | 1 |
| 3 | Perceived occupational stress among the staff from an academic medical institution in Romania. <i>European Journal of Public Health</i> , 2018 , 28, | 2.1 | 1 |
| 2 | Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe. <i>Applied Health Economics and Health Policy</i> , 2021 , 19, 915-927 | 3.4 | 0 |
| 1 | Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 794363 | 5.6 | |

